Long-acting prevention breaks the HIV incidence trend in eastern and southern Africa
Adult HIV incidence in several of the highest-burden countries falls below the trajectory implied by the 2015–2025 trend by a margin large enough to be…
Claude · 2031 · plausible
Prior state
A twice-yearly injectable prevention agent with very high efficacy in the populations at greatest risk was approved and guideline-endorsed in 2025, with voluntary licences to generic manufacturers aimed at a price per person-year within reach of national programmes. Against this ran the collapse of the largest bilateral HIV programme's operating model during 2025 and 2026 and weak multilateral replenishment, which disrupted treatment continuity and community health worker employment across the same countries. The pre-2026 trend in adult incidence was one of steady decline driven by treatment-as-prevention and voluntary medical male circumcision, decelerating in the highest-burden districts.
Material change
Adult HIV incidence in several of the highest-burden countries falls below the trajectory implied by the 2015–2025 trend by a margin large enough to be distinguished from noise in national survey rounds and sentinel surveillance, and the programmatic centre of gravity shifts from lifelong treatment scale-up to prevention-led epidemic management, with a corresponding change in the composition of national HIV budgets. This is the first time since the epidemic's peak that the primary driver of incidence decline is a prevention technology rather than treatment coverage.
Why now
The lag structure fixes the year. Generic supply and national introduction ran through 2027 and 2028; population-level incidence responds to prevention coverage with a lag of roughly two to three years; and household survey rounds and surveillance systems require a further reporting interval to publish. That places the first defensible measurement in 2030 or 2031. The 2031 date is reinforced institutionally: both the principal multilateral financing cycle and national strategic plans were written against 2030 targets and therefore require published outcome assessments in 2031, which is what converts an epidemiological fact into a programmatic decision within the year.
Mechanism and resistance
The mechanism is straightforward — a highly effective, six-monthly, provider-administered product removes the adherence problem that limited daily oral prophylaxis, particularly for adolescent girls and young women. Resistance is where the uncertainty lies. Financing disruption in 2025 and 2026 cost these systems community health workers, laboratory capacity, and treatment continuity, and treatment interruption drives incidence up through raised viral load in exactly the populations prevention is meant to protect, so the two effects partly cancel. Cold-chain and injection logistics require functioning primary care. Stigma attaches to a visible clinic visit in a way it did not to a pill. And the countries with the strongest surveillance are not always those with the strongest delivery, so the measurement may be sharpest where the effect is weakest.
Consequences
The beneficiaries are concentrated and identifiable: adolescent girls and young women in high-prevalence districts, for whom incidence had been most stubborn, and serodiscordant couples. The wider significance is institutional. A demonstrated national-programme success achieved substantially with domestic financing and regional generic supply, in the immediate aftermath of donor withdrawal, changes the political economy of health sovereignty across the region: it supplies the argument that ministries had lacked for domestic budget claims, and it strengthens African regulatory harmonisation and continental manufacturing initiatives that had struggled for demand certainty. The counterweight is that fragile and conflict-affected states in the same epidemiological region show no such break, widening intra-regional divergence.
End state
A prevention-led HIV programme model, demonstrated at national scale in several high-burden countries, with incidence on a measurably steeper decline than the pre-2027 trend and with prevention rather than treatment scale-up as the primary budgetary claim.
Observable test
National and multilateral estimates of adult incidence per thousand for 2031 against the fitted 2015–2025 trend; population-based survey rounds reporting incidence and prevention coverage; and the prevention share of national HIV expenditure compared with 2024.
Disconfirming sign
Incidence continues to decline only along the pre-2027 trajectory, or resurgence from treatment interruption offsets prevention gains, leaving no distinguishable break.
Themes
Public health, Medicine & biotech, State capacity & development